Company

About us

Relief Therapeutics is a Swiss, commercial-stage biopharmaceutical company developing and commercializing through selected partners novel, patent-protected therapies for specialty, rare, and ultra-rare diseases.

Our mission is to redefine treatment paradigms by enhancing efficacy, safety, and convenience, ultimately improving the quality of life for patients with chronic and debilitating conditions. With a lean and agile structure, we apply our expertise in drug delivery systems and drug repurposing to develop innovative therapies targeting rare dermatological and metabolic diseases.

Founded in 2013, Relief has built a diversified portfolio that combines a pipeline of promising drug candidates with revenue-generating, out-licensed products. Our core development programs include RLF-TD011 — a differentiated acid-oxidizing solution of hypochlorous acid for the treatment of epidermolysis bullosa, and RLF-OD032 — a highly concentrated liquid formulation of sapropterin dihydrochloride for the treatment of phenylketonuria.

Management

Relief’s management team strategy is to maintain a lean internal structure and a series of collaborations with contract research organizations, contract manufacturers, licensees and distributors, national clinical networks, and relevant worldwide experts.

Paolo Galfetti | Giorgio Reiner | Jeremy Meinen | Vincenzo Gallo

Vincenzo Gallo

Paolo Galfetti

Chief Business Officer

Mr. Galfetti has more than thirty years of management experience in the pharmaceutical sector including in the areas of business development and licensing, operational strategic management, clinical research and pharmaceutical discovery and development. He held management positions in our organization since 1995 and currently serves as the Company’s Chief Business Officer.

Read more
Giorgio Reiner
Paolo Galfetti

Giorgio Reiner

Chief Scientific Officer

Mr. Reiner has over 30 years of R&D experience. He is leading the development of Relief's pharmaceutical technologies and new products. Mr. Reiner holds a Master's degree in Pharmaceutical Chemistry and Technology from the University of Pharmacy in Milan, Italy.

Read more
Jeremy Meinen
Giorgio Reiner

Jeremy Meinen

CHIEF FINANCIAL OFFICER AND TREASURER

Mr. Meinen serves as Chief Financial Officer and Treasurer. Prior to joining Relief in April 2020, Mr. Meinen provided financial consulting and controlling services to companies in various industries. He is a Swiss certified public accountant and former licensed audit expert.

Read more
Vincenzo Gallo
Jeremy Meinen

Vincenzo Gallo

Head of Legal and Compliance

Mr. Gallo has over 10 years legal expertise in the pharmaceutical industry, gained in both large international and start-up corporations. At Relief, he oversees legal and compliance matters, including employment law and intellectual property.

Read more
Paolo Galfetti

Board
of directors

Relief is strongly supported by a highly knowledgeable Board of Directors with extensive experience in the healthcare industry and capital markets.

RAGHURAM SELVARAJU | Peter de Svastich | Gregory Van Beek | Thomas Elzinga

Thomas Elzinga

Raghuram (Ram) Selvaraju, Ph.D, M.B.A.

Chairman of the Board

Raghuram (Ram) Selvaraju, Ph.D., MBA, is a Managing Director and Senior Healthcare Analyst in the Equity Research Division of H.C. Wainwright & Co., a New York-based full-service investment bank heavily focused on the healthcare sector. He has nearly 20 years of experience on Wall Street and previously was a pharmaceutical researcher at Serono in Switzerland. He holds Ph.D. and M.S. degrees from the University of Geneva and an M.B.A. from Cornell University.

Read more
Peter de Svastich
Raghuram (Ram) Selvaraju, Ph.D, M.B.A.

Peter de Svastich

Member of the Board of Directors

Mr. de Svastich is a Managing Director at GEM. Mr. de Svastich has deep expertise in the areas of commercial banking, investment banking and alternative investments.

Read more
Gregory Van Beek
Peter de Svastich

Gregory Van Beek

Member of the Board of Directors

Mr. Van Beek is a Managing Director at GEM, focusing on special situation investments in both public capital markets and private opportunities. He has 25 years of experience in private equity, portfolio management, investment research and strategy.

Read more
Thomas Elzinga
Gregory Van Beek

Thomas Elzinga

Member of the Board of Directors

Mr. Elzinga is an Investment Associate at GEM. He is responsible for evaluating both public and private investment opportunities, as well as managing portfolio businesses.

Read more
Raghuram (Ram) Selvaraju, Ph.D, M.B.A.